RORγt agonist enhances anti-PD-1 therapy by promoting monocyte-derived dendritic cells through CXCL10 in cancers

BACKGROUND: The overall response rate to checkpoint blockade remains unsatisfactory, partially due to the immune-suppressive tumor microenvironment. A retinoic acid-related orphan receptor γt (RORγt) agonist (LYC-55716) is currently used in clinical trials combined with anti-PD-1, but how the Th17 c...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Li, Tian, Enming, Yu, Mingcheng, Liu, Chenglong, Shen, Lian, Huang, Yafei, Wu, Zhongen, Tian, Jinlong, Yu, Ker, Wang, Yonghui, Xie, Qiong, Zhu, Di
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9034499/
https://www.ncbi.nlm.nih.gov/pubmed/35459193
http://dx.doi.org/10.1186/s13046-022-02289-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9034499/
https://www.ncbi.nlm.nih.gov/pubmed/35459193
http://dx.doi.org/10.1186/s13046-022-02289-2

Ejemplares similares